REPATHA Drug Profile

Summary for Tradename: REPATHA

High Confidence Patents:	15
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for REPATHA
Recent Clinical Trials:	See clinical trials for REPATHA

See drug prices for REPATHA

Recent Clinical Trials for REPATHA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
NewAmsterdam Pharma	PHASE2
National Heart, Lung, and Blood Institute (NHLBI)	Phase 4
Hamad Medical Corporation	Phase 4

See all REPATHA clinical trials

Pharmacology for REPATHA

Mechanism of Action	PCSK9 Inhibitors
Established Pharmacologic Class	PCSK9 Inhibitor
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for REPATHA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for REPATHA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	REPATHA	evolocumab	Injection	125522		2028-08-22	DrugPatentWatch analysis and company disclosures
Amgen Inc.	REPATHA	evolocumab	Injection	125522		2029-05-28	DrugPatentWatch analysis and company disclosures
Amgen Inc.	REPATHA	evolocumab	Injection	125522		2033-04-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for REPATHA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	REPATHA	evolocumab	Injection	125522		2037-05-22	Patent claims search
Amgen Inc.	REPATHA	evolocumab	Injection	125522		2038-06-21	Patent claims search
Amgen Inc.	REPATHA	evolocumab	Injection	125522		2038-06-13	Patent claims search

International Patents for REPATHA

Country	Patent Number	Estimated Expiration
Hong Kong	1143824
Taiwan	201500376
Poland	3666797

Supplementary Protection Certificates for REPATHA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1691026-7	Sweden		PRODUCT NAME: EVOLOCUMAB; EU/1/15/1016, 2015-07-21
CR 2016 00027	Denmark		PRODUCT NAME: EVOLOCUMAB; REG. NO/DATE: EU/1/15/1016 20150721
CA 2016 00037	Denmark		PRODUCT NAME: ALIROCUMAB; REG. NO/DATE: EU/1/15/1031 20150925

Market Dynamics and Financial Trajectory for Repatha

Last updated: March 30, 2026

What is Repatha’s current market position?

Repatha (evolocumab), developed by Amgen, is a monoclonal antibody targeting PCSK9. Approved by the FDA in 2015, it primarily reduces low-density lipoprotein cholesterol (LDL-C). As of 2023, Repatha is listed among the top-tier PCSK9 inhibitors.

The drug generated $1.44 billion in worldwide revenues in 2022, a decline from peak sales above $2.2 billion in 2020. This decrease reflects increased competition from other PCSK9 inhibitors and the expanding use of generic alternatives for related lipid-lowering therapies.

How does Repatha compare to its main competitors?

Drug	Developer	Approval Year	Route of Administration	Listing Price (per injection)	2022 Revenue	Market Share (2022)
Repatha	Amgen	2015	Subcutaneous injection (variable dose)	$585	$1.44B	55%
Praluent	Sanofi/Regeneron	2015	Subcutaneous injection (variable dose)	$498	$550M	25%
Inclisiran	Novartis	2020 (US approval)	Subcutaneous injection (fixed dose twice yearly)	Not yet priced	Not available	5%
Other alternatives	Statins, ezetimibe, fibrates	N/A	Oral	Varies	N/A	residual share

Repatha maintains dominance within prescribed PCSK9 inhibitors but faces pressure from Inclisiran, which offers simplified dosing (biannual injections), potentially impacting market share in the upcoming years.

What are the drivers of market dynamics?

Expanding Clinical Indications

Repatha is approved for familial hypercholesterolemia (FH) and clinical atherosclerotic cardiovascular disease (ASCVD). Off-label and expanded indications, such as heterozygous FH, widen the potential patient base.

Pricing and Reimbursement Policies

Repatha's list price is approximately $585 per injection, with substantial discounts negotiated through payers. CMS and private insurers have implemented value-based agreements, influencing net revenue.

Patent and Regulatory Landscape

Repatha's patent protection is effective until 2030. Patent challenges and biosimilar competition from other PCSK9 inhibitors could influence market share post-2030. Regulatory updates may facilitate biosimilar entry, which could reduce Repatha’s pricing power.

Market Penetration and Physician Adoption

Despite clinical efficacy, Repatha adoption is limited by injection frequency, high costs, and hesitance from healthcare providers to prescribe high-cost biologics over generic alternatives.

How is Repatha’s financial trajectory expected to evolve?

Revenue Projections (2023-2027)

Year	Estimated Revenue	Growth Rate	Remarks
2023	$1.3B	-10%	Slight decline due to increased competition
2024	$1.2B	-8%	Market saturation and continued pricing pressures
2025	$1.1B	-8%	Adoption plateau and generic biosimilars emerge
2026	$1.0B	-9%	Biosimilar options gain traction
2027	$900M	-10%	Patent expiration approaches, biosimilar competition intensifies

Key Revenue Drivers

• Reimbursement and Access: Maintaining favorable payer agreements is critical for revenue stability.
• Pricing Strategies: Price negotiations and value-based contracts will influence net prices.
• Clinical Adoption: Broader guideline inclusion enhances long-term uptake.

R&D and Pipeline Outlook

Amgen maintains a pipeline of next-generation lipid-lowering agents. Early-stage PCSK9 conjugates and gene therapies could impact the market landscape post-2030, possibly reducing reliance on Repatha.

What are the potential market challenges?

• Biosimilar Entry: Entry of biosimilar PCSK9 inhibitors post-2030 could trigger significant price erosion.
• Physician Sentiment: Preference for oral therapies (statins, ezetimibe) remains strong, limiting growth.
• Price Sensitivity: Payer pressure to lower prices could reduce profitability margins.

What is the impact of regulatory and policy shifts?

• U.S. and Global Regulations: Changes in reimbursement policies, step therapy mandates, and value-based pricing may pressure revenues.
• Patent Expiry and Biosimilars: Expected biosimilar competition in 2030 could cut Repatha's revenue by 40-60% over subsequent years.

Key Takeaways

• Repatha’s market share remains substantial but faces decline due to biosimilar threats and competition from oral therapies.
• Revenue is projected to decline approximately 10% annually from 2023 to 2027.
• Reimbursement negotiations, clinical guideline updates, and pipeline advancements are critical factors influencing future trajectory.
• Biosimilar competition is the primary long-term risk starting around 2030.
• Continued innovation and expanded indications could provide revenue stabilization or growth in the near term.

FAQs

How does Repatha's pricing compare internationally?

Pricing varies globally, reflecting healthcare system differences. In Europe, list prices are generally 20-30% lower than U.S., with negotiated discounts. Reimbursement policies influence access and sales volumes.

What is the likelihood of Repatha's market share stabilizing?

Market share stabilization depends on the successful implementation of formulary access, payer negotiations, and physician acceptance. The emergence of more convenient therapies like Inclisiran may accelerate share decline.

Are there any upcoming regulators' decisions that could impact Repatha?

Pending FDA reviews of biosimilars and potential label updates based on new clinical data could influence Repatha's competitiveness and prescribing patterns.

How do patent expirations affect the market?

Patent expiration in 2030 will open the market to biosimilar competitors, likely reducing Repatha’s price and revenues significantly.

What strategic options does Amgen have to sustain revenue?

Diversifying the pipeline into advanced lipid-lowering agents, engaging in value-based contracting, and expanding indications can help offset decline post-2030.

---

Citations:

[1] Amgen Inc. (2023). Annual report 2022. Retrieved from https://investors.amgen.com

[2] Bloomberg Intelligence. (2023). PCSK9 inhibitors market analysis.

[3] U.S. Food and Drug Administration. (2015). Repatha (evolocumab) approval letter.

[4] IQVIA. (2023). Biologic drug sales and market share data.

[5] Novartis. (2022). Inclisiran pipeline and market outlook.